Share this article on:

Editorial introductions

Current Opinion in Infectious Diseases: December 2008 - Volume 21 - Issue 6 - p vii–viii
doi: 10.1097/QCO.0b013e32831a6d3f
Editorial introductions

Current Opinion in Infectious Diseases was launched in 1988. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of infectious diseases is divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline

Section Editors

Tania Sorrell

Figure 1

Figure 1

Professor Sorrell is Professor of Clinical Infectious Diseases and Director of the Centre for Infectious Diseases and Microbiology at the Western Clinical School of the University of Sydney, Westmead, New South Wales. Her longstanding interest in mycology and infections in the immunocompromised host developed following completion of her Medical degree and PhD in Clinical Immunology at the University of Adelaide. She trained in Infectious Diseases at Harbor-UCLA Medical Centre, returning to Westmead Hospital and the University of Sydney in 1979 to establish the first Clinical Infectious Diseases Program in Internal Medicine in Australia and continue her research into host-phagocyte interactions.

Since the mid 1990s, Professor Sorrell's research has focussed on the pathogenesis of fungal infections, new antifungal drug development, new diagnostics and clinical trials of antifungal diagnostic and treatment strategies. She has served on state and national advisory committees in Infectious Diseases and therapeutics and the Research and Human Ethics Committees of the National Health and Medical Research Council of Australia.

Back to Top | Article Outline

Simon Croft

Figure 2

Figure 2

Simon Croft is Professor of Parasitology in the Department of Infectious and Tropical Diseases at the London School of Hygiene & Tropical Medicine, London, UK. He trained as a parasitologist at the Liverpool School of Tropical Medicine and, after post-doctoral periods working in the laboratory on parasite ultrastructure and biochemistry and overseas on the transmission of African trypanosomiasis, he moved to research on anti-protozoal chemotherapy. His expertise and knowledge on anti-protozoal chemotherapy was developed while working with the Wellcome Research Laboratories, Beckenham, UK for 5 years in the 1980s. Following his return to academia, Simon focused his research on the identification and evaluation of novel drugs and formulations for the treatment of leishmaniasis, malaria, human African trypanosomiasis (sleeping sickness) and South American trypanosomiasis (Chagas disease). This work included projects on miltefosine, AmBisome and topical paromomycin, all of which reached clinical trials for the treatment of leishmaniasis. Other current research interests include the drug – immune response interaction and drug resistance in leishmaniasis and malaria. From 2004 to 2007 he was R & D Director at the Drugs for Neglected Diseases Initiative (DNDi), Geneva.

Back to Top | Article Outline

Deenan Pillay

Figure 3

Figure 3

Deenan Pillay is Professor of Virology, and Head of the Research Department of Infection, at University College London. He is also Head of HIV and Antivirals at the Centre for Infections, Health Protection Agency, Colindale. Following a PhD in Biochemistry, Dr Pillay studied Medicine in Newcastle upon Tyne and undertook postgraduate training in medical virology at St Thomas's Hospital and Royal Free Hospital, London. He was then a visiting NIH Fellow in the laboratory of Dr Doug Richman, University of California, San Diego, where he developed an interest in HIV Drug Resistance. On his return to the UK, Dr Pillay took up the post of Consultant Medical Virologist, Birmingham Public Health Laboratory and in 1996 became Director of the National PHLS Reference Laboratory for antiviral drug resistance. In 2003 he moved to University College London, with a joint appointment at the Central Public Health Laboratory, Colindale, where he is pursuing academic and epidemiological studies on drug resistance, with particular reference to HIV.

Dr Pillay's main areas of interest are the treatment of viral infections and laboratory monitoring of such treatment. His current research is focused on clinical correlates of antiviral drug resistance, viral informatic approaches to antiviral drug resistance data, and epidemiology of drug resistance.

© 2008 Lippincott Williams & Wilkins, Inc.